Contribute Try STAT+ Today

Greetings, everyone. Damian Garde here once more, filling in for Ed Silverman to bring you headlines from around the pharma universe as we head into a long weekend.

FDA Commissioner Dr. Robert Califf hasn’t heard a peep from the Trump transition team. That’s according to this interview with The Washington Post, in which the former Duke cardiologist says he’ll be content no matter what happens. “Everyone who knows me knows I have just had fun every day on the job,” Califf told the Post. In the meantime, Califf took pains to point out how it important it is that the FDA determine whether medicines work before approving them, comments perhaps aimed at any potential successors who might take a more laissez-faire approach to the agency.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.